Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21047782 | 1.00 | CYP1A2 (0.39) | CYP1A2CES2CTSLCTSBGMNN | |
| SCHEMBL21047885 | 1.00 | CYP1A2 (0.39) | CYP1A2CES2CTSLCTSBGMNN | |
| SCHEMBL21047731 | 1.00 | CYP1A2 (0.39) | CYP1A2CES2CTSLCTSBGMNN | |
| SCHEMBL21047750 | 1.00 | CYP1A2 (0.39) | CYP1A2CES2CTSLCTSBGMNN | |
| SCHEMBL21047865 | 0.98 | CYP1A2 (0.36) | CYP1A2CYP2C9 | |
| SCHEMBL21047841 | 0.92 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL21047594 | 0.84 | — | — | |
| SCHEMBL15271476 | 0.82 | THRB (0.40) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL15270730 | 0.82 | THRB (0.40) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL15271194 | 0.82 | THRB (0.40) | CES2CTSLCTSBGMNNTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-109563016-B | Method for producing perfluoroalkyl compound using monohydroperfluoroalkane as starting material | 关东电化工业株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
| CN-109563016-A | Using single hydrogen perfluoro alkane as the manufacturing method of the all-fluoroalkyl compound of starting material | 关东电化工业株式会社 | 2019-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | CYP1A2 212/4885CES2 1188/4885CTSL 2041/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | CYP1A2 212/4885CES2 1188/4885CTSL 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.